ArticleClinical endocrinology2025
Postoperative Unstimulated Thyroglobulin Accurately Predicts Outcomes in High-Risk Differentiated Thyroid Cancer: A Retrospective Cohort Study.
Article in Clinical endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Influencing factors and model predictive analysis of the efficacy of adjuvant ¹³¹I therapy after DTC surgery.Frontiers in oncology · 2026Article
- Development and validation of a machine learning model for predicting high-risk distant metastatic recurrence in differentiated thyroid cancer.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveHigh-risk differentiated thyroid cancer (DTC) patients show variable outcomes. While postoperative stimulated thyroglobulin (STg) is a recognized predictive marker, the prognostic significance of unstimulated thyroglobulin (UTg) is still unexplored. This study aims to assess the prognostic value of postoperative UTg in high-risk DTC patients.
designRetrospective cohort study (2015-2024) at two Brazilian tertiary hospitals. PATIENTS: One thousand DTC patients were identified, of which 144 were high-risk. Fifty seven patients met the inclusion criteria.
methodsClinical, pathological, and laboratory data were collected. Outcomes were categorized as favorable (excellent/indeterminate responses) or unfavorable (biochemical/structural incomplete responses). Receiver Operating Characteristic (ROC) curves determined cutoff values for predicting outcomes and metastases.
resultsSignificant predictors of unfavorable outcomes included advanced age (p = 0.048), larger tumor size (p = 0.002), higher UTg (p < 0.001), and STg (p < 0.001). UTg was an independent risk factor for 1-year outcomes (OR = 0.008; 95% CI: 0.001-0.088; p < 0.001). UTg cutoff of 2.1 ng/mL distinguished outcomes with high sensitivity (83.3%), specificity (96.0%), and accuracy (90.7%). A higher cutoff of 3.8 ng/mL identified metastases (sensitivity 86.4%, specificity 90.5%). UTg showed non-inferiority to stimulated thyroglobulin (STg) in predicting outcomes (p = 0.964) and metastasis (p = 0.980).
conclusionPostoperative UTg is a strong prognostic marker in high-risk DTC patients, providing a non-inferior alternative to STg with greater accessibility and fewer side effects. We propose a clinical algorithm to optimize the management of these cases. When UTg levels exceed 2.1 ng/mL, particularly higher than 3.8 ng/mL, investigation of potentially resectable metastatic foci should be considered before radioiodine therapy. Prospective studies are needed to validate this algorithm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.